Back to results
US 2024/0226304 A1Published application
Lipopeptide fusion inhibitors as sars-cov-2 antivirals
AssigneesThe Trustees of Columbia University in the City of New York, Erasmus University Medical Center, Inserm
InventorsMatteo POROTTO, Anne MOSCONA, Rik DE SWART, Rory DE VRIES, Branka HORVAT, Cyrille MATHIEU
Life of this patent
Estimating the term…
Abstract
Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.
Claims21
1-56. (canceled)
A SARS-COV2 (COVID-19) lipid-peptide fusion inhibitor comprising two peptides each comprising SEQ ID NO:1, two PEG moieties, and one cholesterol tag.
A SARS-COV2 (COVID-19) lipid-peptide fusion inhibitor comprising two peptides each comprising SEQ ID NO:1, one cholesterol tag, and means for linking the two peptides to the cholesterol tag.
Dependencies are inferred from the claim text.